Next month, representatives of national governments will gather in the Japanese city of Nagoya to agree on how companies should share the profits of chemical and drug development with the nations that provided the original biological material.rnAs part of the Convention on Biological Diversity, the proposed International Regime on Access and Benefit-Sharing aims to tackle so-called biopirates who do not share such proceeds with the source country. To stamp out biopiracy is a laudable ambition, but the new rules seem likely to pose serious problems for the field in which I work: biological control.
展开▼
